Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer

Flaig, Thomas W., Glodé, Michael, Gustafson, Daniel, van Bokhoven, Adrie, Tao, Yuzhen, Wilson, Shandra, Su, Lih‐Jen, Li, Yuan, Harrison, Gail, Agarwal, Rajesh, Crawford, E. David, Lucia, M. Scott, Pollak, Michael · 2010 · The Prostate

Abstract

BACKGROUND: Silibinin is a polyphenolic flavonolignan derived from milk thistle (Silybum marianium) with anti‐oxidant properties. The purpose of the current trial was to determine the tissue and blood effects of high‐dose silybin‐phytosome in prostate cancer patients. METHODS: Subjects with localized prostate cancer planning for a prostatectomy were eligible to enroll. Six patients received 13 g of silybin‐phytosome daily with six additional participants serving as control subjects. RESULTS: Patients in the treatment arm received silybin‐phytosome for 14–31 days (mean was 20 days) prior to surgery. Silibinin blood levels were measured 1 hr after the first silybin‐phytosome dose with a mean value of 19.7 µM. Trough silibinin levels were assessed at the end of the trial with an average concentration of 1.2 µM. In contrast to the high peak levels of silibinin observed in blood, the highest silibinin level observed in the harvested prostate tissue was 496.6 pmol/g. There were no significant differences noted in baseline and post‐treatment blood levels of IGF‐I and IGFBP‐3. One of the treated patients developed a grade 4 post‐operative thromboembolic event. The other observed toxicities in the treatment group were mild: four subjects had diarrhea and one had asymptomatic grade 2 hyperbilirubinemia which was transient. CONCLUSIONS: High‐dose oral silybin‐phytosome achieves high blood concentrations transiently, but low levels of silibinin are seen in prostate tissue. Silibinin's lack of tissue penetration may be explained by its short half‐life, the brief duration of therapy in this study or an active process removing silibinin from the prostate. Prostate 70: 848–855, 2010. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.21118

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 193

Metadata

Authors
Flaig, T. W., Glodé, M., Gustafson, D., van Bokhoven, A., Tao, Y., Wilson, S., Su, L., Li, Y., Harrison, G., Agarwal, R., Crawford, E. D., Lucia, M. S., & Pollak, M.
Venue
The Prostate
Publisher
Wiley
Published
2010-02
Volume
70
Issue
8
Pages
848-855
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2088244733
Cited by
193
References
2
FWCI
11.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.